Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Post Stroke, Anxiety, Depression
Phase NA
Enrollment 132
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Numerous studies have highlighted how individualized music listening favors motor, cognitive, and emotional recovery in post-stroke patients, stimulating neuroplasticity and cerebral connectivity. However, gaps persist regarding the standardization of protocols and the neural mechanisms involved. This study aims to bridge these gaps with a rigorous scientific approach, integrating clinical assessments and neuroimaging. This is a multicenter randomized controlled single-blind trial. Subjects will be allocated into 2 groups: an experimental group subjected to a 4-week intervention of daily Therapeutic Music Listening sessions (Raglio, 2023) in addition to conventional therapeutic interventions (standard care), and a control group subjected solely to conventional therapeutic interventions (standard care). A follow-up is scheduled for one month after the conclusion of treatment. The study duration is 24 months and the screening phase will be continuous until the conclusion of planned recruitment. Primary objective of the study is to evaluate the efficacy of Therapeutic Music Listening (TML) on anxiety in post-stroke patients. Secondary objective of the study is to investigate other possible effects on depression, quality of life, cognitive aspects (specifically attention and memory), and on connectivity via functional Magnetic Resonance Imaging (fMRI). Primary endpoint is the reduction of anxiety. Secondary endpoint is the improvement in depression, quality of life, cognitive functions, and cerebral connectivity parameters.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Music intervention — The intervention will be managed by a professional music therapist with the collaboration of an operator. The music therapist collects data on the clinical history and musical preferences of the patient, which are integrated with the use of specific musical parameters and structures to create personalized playlists lasting 40 minutes. Such playlists aim to reflect the musical tastes of the patient and at the same time to obtain therapeutic objectives inducing relaxation, activation or distraction, depending on the clinical needs. The listening sessions take place daily for one month at a time of day chosen with the patient, who listen to the playlist through the use of a tablet and headphones. The music therapist submits to the patient a brief questionnaire after the first listening and then weekly, to verify the impact of music listening and possibly modify the playlist in line with the patient's feedback and the evolution of the treatment.
  • Other: Control group — Standard treatment is based on daily rehab activities (physical therapy and/or occupational therapy) and weekly psychological support sessions.

Primary Outcomes

  • Effectiveness of Therapeutic Music Listening (TML) on anxiety in post stroke patients (From enrollment (T0) to the end of treatment at 4 weeks (T1) and follow-up at 8 weeks (T2).)
  • Effectiveness of Therapeutic Music Listening (TML) on depression in post stroke patients (Time Frame: From enrollment (T0) to the end of treatment at 4 weeks (T1) and follow-up at 8 weeks (T2).)
  • Effectiveness of Therapeutic Music Listening (TML) on quality of life in post stroke patients (Time Frame: From enrollment (T0) to the end of treatment at 4 weeks (T1) and follow-up at 8 weeks (T2).)
  • Effectiveness of Therapeutic Music Listening (TML) on cognitive outcomes in post stroke patients (Time Frame: From enrollment (T0) to the end of treatment at 4 weeks (T1) and follow-up at 8 weeks (T2).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-12
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 132 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Istituti Clinici Scientifici Maugeri SpA
Collaborators: Armonica Onlus Foundation
Contact Information
Study Contact:
Alfredo Raglio
+39 3387291944
alfredo.raglio@icsmaugeri.it
Alfredo Raglio
+39 03825921
alfredo.raglio@icsmaugeri.it
Fondazione Salvatore Maugeri I.R.C.C.S.
Interventions
  • Other: Music intervention — The intervention will be managed by a professional music therapist with the collaboration of an operator. The music therapist collects data on the clinical history and musical preferences of the patient, which are integrated with the use of specific musical parameters and structures to create personalized playlists lasting 40 minutes. Such playlists aim to reflect the musical tastes of the patient and at the same time to obtain therapeutic objectives inducing relaxation, activation or distraction, depending on the clinical needs. The listening sessions take place daily for one month at a time of day chosen with the patient, who listen to the playlist through the use of a tablet and headphones. The music therapist submits to the patient a brief questionnaire after the first listening and then weekly, to verify the impact of music listening and possibly modify the playlist in line with the patient's feedback and the evolution of the treatment.
  • Other: Control group — Standard treatment is based on daily rehab activities (physical therapy and/or occupational therapy) and weekly psychological support sessions.
Study Locations (1 sites)
Fondazione Salvatore Maugeri I.R.C.C.S., Pavia, 27100 Italy
Eligibility Criteria
Inclusion Criteria: * Diagnosis of first ischemic or hemorrhagic stroke verified by Computerized Axial Tomography or Magnetic Resonance * Age above 18 years * Mini Mental State Examination ≥ 24 * Latency from the event \< 3 months * Presence of clinically significant anxiety and/or depression (Generalized Anxiety Disorder and/or Patient Health Questionnaire ≥10) * Onset of acute event not more than 90 days prior to enrollment in the study Exclusion Criteria: * Clinical instability * Lesions dated over 3 months from onset * Multiple or bilateral lesions * Mini Mental State Examination \< 24 * Previous or concomitant neurological, psychiatric, or internal pathologies found in the year preceding the study that, in the judgment of the clinical investigator, may affect the psychological condition and/or interfere with study procedures * Behavioral/cognitive disorders that prevent adequate patient compliance with treatment * Therapeutic-rehabilitative treatments with music in the year preceding the study * Previous musical skills (training or musical practice lasting more than 3 years) * Refusal or impossibility to sign informed consent For the subgroup of patients subjected to functional Magnetic Resonance, the following exclusion criteria will also be taken into account: * Incompatibility with the execution of the MRI investigation (e.g., ascertained or possible presence of metal in the body; claustrophobia; sickle cell anemia) * Inability to understand or provide informed consent for the execution of the MRI investigation
Conditions Rhinitis, Rhinoconjunctivitis
Phase PHASE3
Enrollment 736
Locations 19 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if MM09 works to treat patients allergic to house mites, displaying rhinitis/rhinoconjunctivitis with or without mild to moderate asthma. It will also learn about the safety of MM09. The main questions it aims to answer are: Does MM09 reduce the symptoms and the need of rescue medication? What medical problems do participants have when inhaling MM09? Researchers will compare MM09 to a placebo (a look-alike substance that contains no drug) to see if MM09 works to treat rhinitis/rhinoconjunctivitis.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Biological: Allergen Immunotherapy Extract — Sublingual spray, solution

Primary Outcomes

  • RCSMS : Rhinitis/Rhinoconjunctivitis Combined Symptom and Medication Score (last 4 weeks of IMP treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-04-02
Completion: 2029-07
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 736 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Inmunotek S.L.
Principal Investigators:
  • Raquel Caballero (STUDY_CHAIR) - Inmunotek S.L.
Contact Information
Study Contact:
Raquel Caballero
+34 912 908 94
rcaballero@inmunotek.com
Iris V Medina
+54 9 2317 47 4535
irisvmedina@gmail.com
Centro Médico Vitae
Ledit R Ardusso
+54 9 341 6426843
cic-iesr@hotmail.com
Centro de Investigaciones Clínicas - Instituto de Especialidades de la Salud Rosario
Interventions
  • Biological: Allergen Immunotherapy Extract — Sublingual spray, solution
Study Locations (19 sites)
Centro Médico Vitae, Nueve de Julio, Buenos Aires 1650 Argentina
Centro de Investigaciones Clínicas - Instituto de Especialidades de la Salud Rosario, Rosario, Santa Fe Province 2000 Argentina
Centro Respiratorio Infantil, Rosario, Santa Fe Province 2000 Argentina
Fundación CIDEA, Buenos Aires, 1121 Argentina
Hospital Italiano de Buenos Aires, Buenos Aires, 1199 Argentina
Centro de Educación Medica de Investigaciones Clinicas "Norberto Quirno" (CEMIC), Buenos Aires, 1431 Argentina
Beijing Tongren Hospital, Beijing, Beijing Municipality 100730 China
The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangzhou 510080 China
The First Affiliated Hospital, Sun Yat-sen University, Zhongshan, Guangzhou 510080 China
The Third Xiangya Hospital of Central South University, Xiangya, Hunan 410013 China
Eligibility Criteria
Inclusion Criteria: 1. Participants who have signed and dated Informed Consent Form (ICF). 2. Female or male aged 12 to 65 years, both included, at the time of signature of ICF. 3. Participants with confirmed clinical history of inhalation allergy with intermittent or persistent moderate-severe rhinitis/ rhinoconjunctivitis according to the ARIA classification(1) of at least 1 year of duration (treated with anti-allergic medication) with or without mild-moderate controlled intermittent or persistent asthma according to the definition of GINA 2022(2) caused by Dermatophagoides pteronyssinus and/or Dermatophagoides farinae. 4. Participants with positive skin prick test and a wheal major diameter ≥ 5 mm to a standardized allergen extract of Dermatophagoides pteronyssinus and/or Dermatophagoides farinae. 5. Women of childbearing age (i.e., following menarche and until postmenopause, defined as no menses for 12 months without an alternative medical cause, or non-subject to permanent sterilisation methods, such as hysterectomy, bilateral salpingectomy and bilateral oophorectomy) must have a serum pregnancy test negative result, and a confirmed menstrual period before enrolling the study. 6. Women of childbearing age must commit to using a highly effective contraception method during the trial and up to 1 month after the end of treatment with the investigational medicinal product (IMP). Such methods include: combined (estrogen and progestogen containing) hormonal, contraception. associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device, intrauterine hormone-releasing system, male condom, diaphragm used with spermicide, bilateral tubal occlusion, vasectomized partner or sexual abstinence. 7. Participants capable of complying with dosage regimen. 8. Participants owning a smartphone to register symptoms and medication consumption. 9. Participants not sensitized to any other clinically relevant allergen or sensitized with the following characteristics (sensitization to other allergens will be assessed through skin prick test in Europe and LATAM and through IgE levels in China): 1. Participants sensitized to dander (with a positive skin prick test for dander or IgE ≥ 0.35 kU/L), provided that they have occasional exposure and symptoms. 2. Participants sensitized to endemic pollen (with a positive skin prick test or IgE ≥0.35 kU/L) will be scheduled to be included so that the pollen season does not coincide with the Baseline Evaluation Period nor with one month before and after the Main Evaluation Period. In LATAM, grass sensitized participants will not be included. 10. Participants not sensitized to moulds, cockroach, Blomia tropicalis or other geographically relevant mites (negative skin prick test or IgE \< 0.7 kU/L). 11. Participants with a RCSMS ≥ 3 out of 6 recorded for at least 10 days during the baseline evaluation period, corresponding to moderate-to-severe allergic rhinitis/rhinoconjunctivitis. 12. Participants with specific IgE against a complete extract of D. pteronyssinus and / or D. farinae or any of the molecular components of allergenic sources with a value ≥ 3.5kU/L. Exclusion Criteria: 1. Participants who have received previous immunotherapy to any of the tested allergen during the last 5 years or any desensitization process in the last 2 years (e.g., oral immunotherapy \[OIT\], milk, or egg) before the second screening visit (S2), or currently receiving immunotherapy with any other allergen. 2. Those cases in which allergen-specific immunotherapy (AIT) would be a contraindication according to the criteria of European Allergy and Clinical Immunology Immunotherapy Subcommittee.(3) 3. Asthmatic participants with forced expiratory volume in the first second (FEV1) \<80% (following at least a 6-hour washout of short-acting beta2 agonists \[SABA\] and 12-hour washout of long-acting beta2 agonists \[LABA\]) despite pharmacological treatment by the time of enrolment. 4. Participants with uncontrolled asthma, according to GINA 2022,(2) asthma with poor symptom control (frequent symptoms or reliever use, activity limited by asthma, night waking due to asthma) and/or frequent exacerbations (≥2/year) requiring oral corticosteroids (OCS), or serious exacerbations (≥1/year) requiring hospitalization. 5. Participants with severe asthma, according to GINA 2022,(2) on Step 4 or 5 treatment, who had poor symptom control and had good adherence and inhaler technique. 6. Participants on treatment with β-blockers or angiotensin-converting enzyme (ACE) inhibitor. 7. Participants on treatment with immunosuppressive or biological drugs. 8. Participants who had not had a long enough washout/withdrawal period at the first screening visit (S1) according to criteria in the study protocol (See Table 6 in section 9.5.3) before undergoing allergen diagnostic tests (skin prick test or IgE analysis). 9. Unstable participants who have suffered a respiratory tract infection and/or asthma exacerbation within 4 weeks prior to first screening visit (S1). 10. Participants who have suffered chronic urticaria, severe anaphylaxis, or with hereditary angioedema history within 2 years prior to the first screening visit (S1). 11. Participants having any contraindication for the use of adrenaline (e.g., hyperthyroidism, heart disease, or hypertension) according to the investigator's criteria. 12. Participants with other severe diseases not related to allergic rhinitis or asthma that could interfere with the study treatment or the follow-up. 13. Participants with severe and unresponsive to treatment autoimmune diseases (e.g., thyroiditis or lupus), tumoral diseases or immunodeficiencies. 14. Participants that could not comply with the study protocol, according to the investigator's criteria, or have a serious mental illness. 15. Participants with known allergy to any of the components of the study treatment other than study allergens. 16. Participants who had a complication(s) of any nasal disease (including nasal polyp, nasal septal deviation, and hypertrophic rhinitis, drug-induced rhinitis and/or non-allergic rhinitis) affecting an appropriate evaluation of the efficacy and/or safety, according to investigator's criteria. 17. Participants who had a nasal surgery within 6 months prior to the first screening visit (S1) or have programmed or anticipated nasal surgery during the trial period. 18. Participants with a lesion in the oral cavity that could confound the safety profile of the study treatment, according to the investigator's criteria. 19. Participants who required treatment with antihistamines and/or corticosteroids for other purposes than alleviating symptoms of allergic rhinitis (except temporal use for diseases such as common colds). 20. Participants with lower respiratory tract diseases different from asthma as emphysema, bronchiectasis, or chronic obstructive pulmonary disease. 21. Breastfeeding or pregnant women. 22. Participants who are immediate family members of the investigator. 23. Concurrent participation in other clinical trials or previous participation within 30 days prior to the first screening visit (S1). 24. Participants with history of serious systemic reactions, including food, Hymenoptera venom, medications, etc. 25. Participants expected to have marked changes (e.g., moving) in the circumstances of life during the study. 26. Participants who plan to start using anti-mite bedding or similar equipment during the study. 27. Participants who are considered inappropriate for the study, according to the investigator criteria.
Conditions Brain Cancer Metastatic, CMV Viremia
Phase PHASE2
Enrollment 28
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a phase II trial with an initial safety lead-in evaluating the efficacy, safety, neurocognitive, and quality-of-life outcomes of anti-cytomegalovirus (CMV) therapy and standard-of-care (SOC) in patients with anti-human cytomegalovirus (HCMV)-reactivated brain metastases. Male and female patients, aged ≥18 years, who have metastatic breast cancer with progressive brain metastases and CMV viremia (\> 250 copies/ml) or positive CMV IgG or IgM will be eligible to participate in the trial. Patients can proceed with SRS as long as at least 1 lesion which is 2 cm or less in a noncritical area in the brain is spared as per the discretion of treating neurosurgeon/radiation oncologist. At least 10 patients will be enrolled in the initial safety lead-in followed by the Phase II trial which will include 18 patients. Anti-HCMV therapy, oral Valganciclovir will be given to patients at 900 mg twice a day for 2 weeks. After the induction period, the maintenance will be continued with valganciclovir at 450 mg twice daily for 4 weeks (28 days).

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Valganciclovir — Valganciclovir inhibits viral DNA polymerase, effectively controlling HCMV reactivation and its associated immunosuppressive effects. Dosing for oral Valganciclovir will be based on standard of care dosing as per FDA in patients with HCMV infection. Dose adjustments will be made by the principal investigator for renal function, treatment-related AEs and disease progression according to the manufacturer's recommendations as they are present in individuals and will be assessed on a case-by-case basis.

Primary Outcomes

  • Objective Response Rate with anti-HMCV Therapy and SOC (6 Weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-07-14
Completion: 2030-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 28 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Methodist Hospital Research Institute
Principal Investigators:
  • Akshjot Puri, M.D. (PRINCIPAL_INVESTIGATOR) - The Houston Methodist Hospital Research Institute
Contact Information
Study Contact:
Milan Sheth
346-238-7169
mksheth2@houstonmethodist.org
Titilayo Olubajo
713-363-9803
tolubajo@houstonmethodist.org
Akshjot Puri, M.D.
713-441-0687
apuri@houstonmethodist.org
Houston Methodist Neal Cancer Center
Interventions
  • Drug: Valganciclovir — Valganciclovir inhibits viral DNA polymerase, effectively controlling HCMV reactivation and its associated immunosuppressive effects. Dosing for oral Valganciclovir will be based on standard of care dosing as per FDA in patients with HCMV infection. Dose adjustments will be made by the principal investigator for renal function, treatment-related AEs and disease progression according to the manufacturer's recommendations as they are present in individuals and will be assessed on a case-by-case basis.
Study Locations (1 sites)
Houston Methodist Neal Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: 1. Male or female aged \>18 years at the time of consent 2. Breast cancer with progressive brain metastases supra and/or infratentorial. Patients can proceed with SRS as long as at least 1 lesion which is 2 cm or less in a noncritical area in the brain is spared as per the discretion of treating neurosurgeon/radiation oncologist. 3. At least one non irradiated, untreated progressive brain metastases site 4. Serum HCMV DNA by real time PCR \> 250 copies/ml or positive CMV Ig G or Ig M. 5. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol. If the patient is unable to consent for any reason a legally authorized guardian may provide consent on their behalf. Written informed consent and any locally required authorization (e.g., Health Insurance Portability and Accountability Act) will be obtained from the patient prior to performing any protocol-related procedures, including screening evaluations. 6. Metastatic breast cancer who has systemically no evidence of disease, complete remission, partial remission, stable or progressive disease 7. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2 8. Adequate hematology without ongoing transfusion support (hemoglobin \> 9 g/dl, absolute neutrophil count (ANC) \> 1500 per mm3 , platelets \> 100,000 per mm3) 9. Adequate renal and hepatic function (creatinine clearance \[CrCL\] \> 60 mL/min, bilirubin x:≤1.5 upper limit of normal (ULN), aspartate aminotransferase \[AST\] and alanine aminotransferase \[ALT\] ≤ 2.5 x ULN and serum albumin ≥ 3 g/dl. 10. Other CMV treatment if clinically indicated per physician's choice 11. Evidence of postmenopausal status or negative serum pregnancy test for premenopausal female patients. Negative serum β-human chorionic gonadotropin pregnancy test within 7 days prior to the first dose of study treatment for premenopausal patients. Women will be considered postmenopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: 12. Women \<50 years of age would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the postmenopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy). 13. Women ≥50 years of age would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \>1 year ago, had chemotherapy-induced menopause with last menses \>1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy). 14. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow-up. Exclusion Criteria: 1. Single resectable intracranial lesion 2. Last intracranial progression free survival \> 12 months 3. All progressive brain metastases have been radiated 4. Brain metastases needing immediate local intervention such as mass effect, herniation, active neurological symptoms, increased intracranial pressure, those near vital structures like the motor cortex, proximity to the optic nerve/chiasm or brain stem etc (can still be included if there are any other non-radiated progressive brain metastases) Multidisciplinary discussion with neurosurgery and radiation oncology will be needed to determine which patients may be safely enrolled on the trial. 5. Active pregnancy or breast feeding 6. Women of childbearing potential or fertile men unwilling to use effective contraception (Section 6.2, Table 6) during study and up to three months after treatment discontinuation. 7. Known psychiatric disorder that causes poor cooperation with the trial requirements. 8. Participants with previous other malignancies must have had at least a 3-year disease free interval, except those with non-melanoma skin cancer or carcinoma in situ of cervix 9. Participation in another clinical study with an investigational product within 28 days prior to the first dose of study treatment. 10. Concurrent enrollment in another clinical study unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study. 11. Unresolved or unstable adverse events (AEs) from prior administration of another investigational drug, per investigators' discretion. 12. Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of study treatment. 13. Non-English-speaking subjects will not be enrolled in this study since the neurocognitive tests including DKEFS, RAVLT and TMT are not validated to be scored in other languages.
Conditions Cancer, Breast Cancer, Prostate Cancer, ...
Phase NA
Enrollment 180
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Genetic testing can alter therapy and surgical management for cancer patients and is therefore indicated as a first-line test for many newly diagnosed patients, including breast, ovarian, pancreatic, prostate and colon/GI patients. To reduce pressure on already constrained genetics clinics across Canada, some cancer centres are 'mainstreaming' genetic testing - whereby genetic testing is initiated and mediated by oncologists without traditional pre-test genetic counseling (GC) often using some form of paper-based patient pamphlets or videos. There is no standard, evidence-based approach to mainstreaming, leading to significant practice variation, a lack of coordinated care and ultimately, negative psychological impacts on patients. Digital solutions can address these gaps by providing a standardized, coordinated and patient-centered approach to deliver cancer genetic education. However, digital solutions for providing cancer genetics services are uncommon and clinical-effectiveness and service delivery outcomes have not been well-assessed. This study will test a digital mainstreaming platform called the Genetics Adviser for Mainstream care to assess its effectiveness in improving psychological outcomes and patient-centred care for mainstream cancer patients compared to standard of care.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: Genetics Adviser for Mainstream Care (GA-Mainstream) — The Genetics Adviser for Mainstream Care will educate participants on cancer genetic testing after oncologist-initiated genetic testing. Participants may also receive their results on the GA-Mainstream.
  • Behavioral: Mainstreaming Standard of Care — After oncologist-initiated genetic testing, participants may not receive additional information prior to the receipt of their results or they may receive educational materials on cancer genetic testing. Results will be disclosed by either a genetic counselor or oncologist with post-test counseling of select patients.

Primary Outcomes

  • Test Specific Distress - Multi-Dimensional Impact of Cancer Risk Assessment (MICRA) (Assessed immediately after return of results via intervention (intervention arm only). Assessed at 2-weeks (primary timepoint) and 6 weeks post-return of results for everyone.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-30
Completion: 2027-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Unity Health Toronto
Principal Investigators:
  • Yvonne Bombard, PhD (PRINCIPAL_INVESTIGATOR) - St. Michael's Hospital and University of Toronto
Contact Information
Study Contact:
Marc Clausen, MA
416-864-6060
marc.clausen@unityhealth.to
Daniel Assamad, MHSc
d.abdassamad@mail.utoronto.ca
Marc Clausen, MA
416-864-6060
Marc.Clausen@unityhealth.to
Sunnybrook Hospital
Interventions
  • Behavioral: Genetics Adviser for Mainstream Care (GA-Mainstream) — The Genetics Adviser for Mainstream Care will educate participants on cancer genetic testing after oncologist-initiated genetic testing. Participants may also receive their results on the GA-Mainstream.
  • Behavioral: Mainstreaming Standard of Care — After oncologist-initiated genetic testing, participants may not receive additional information prior to the receipt of their results or they may receive educational materials on cancer genetic testing. Results will be disclosed by either a genetic counselor or oncologist with post-test counseling of select patients.
Study Locations (2 sites)
Sunnybrook Hospital, Toronto, Ontario M4N 3M5 Canada
Mount Sinai Hospital, Toronto, Ontario M5G 1X5 Canada
Eligibility Criteria
Inclusion Criteria: * Receiving germline testing related to primary cancer condition initiated by oncologist * 18 years old or older. * Speak and read English Exclusion Criteria: * Receiving cancer genetic testing via a referral to a genetics clinic * Do not speak or read English * Under 18 years of age * Determined to have diminished, marginal and or fluctuating decisional capacity * Lack access to internet or an electronic device
Conditions Type 2 Diabetes Mellitus
Phase Not Applicable
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

In this non-interventional study, the effectiveness and tolerability of Lusefi® in adult patients with type 2 diabetes will be evaluated.

Design

Study type: Observational Observational model: Other Time perspective: Cross Sectional

Primary Outcomes

  • Hypoglycemic effectiveness of luseogliflozin in patients with type 2 diabetes (glycated hemoglobin) (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-03-02
Completion: 2027-09-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Servier Russia
Principal Investigators:
  • Marina Shestakova (PRINCIPAL_INVESTIGATOR) - Endocrinology Research Centre
Contact Information
Study Contact:
Ekaterina Erina
+7 495 9370700
ekaterina.erina@servier.com
Interventions
N/A
Study Locations (1 sites)
GBUZ hospital, Anapa, Russia
Eligibility Criteria
Inclusion Criteria: * Men and women aged 18 years and older. * Patients with type 2 diabetes. * Written informed consent of the patient to participate in the study. * No conditions that require emergency medical aid. * Treatment with luseogliflozin started 7 to 30 days prior to the inclusion visit as part of routine clinical practice and in accordance with the SmPC approved in the Russian Federation. * Presence of data on the parameters of interest (HbA1c, eGFR, BP, body weight), dated no later than 15 days from the date the treatment with luseogliflozin was started Exclusion Criteria: * Patients cannot be included in this study if they meet at least one of the following exclusion criteria: * Known hypersensitivity to luseogliflozin or other components of Lusefi®. * Type 1 diabetes. * Decompensated type 2 diabetes. * Pregnancy, breastfeeding, or planned pregnancy during the study and at least two months after the study. * Severe renal failure (eGFR \<30 mL/min/1.73 m2), end-stage chronic kidney disease (CKD) or dialysis, as the treatment is predicted to be ineffective in this population of patients. * Diabetic ketoacidosis, diabetic coma or precoma. * Severe infections, pre- and postoperative period, or severe injury. * Any suspected or confirmed malignant neoplasm, including a history of malignancy within ≤5 years prior to screening, excluding successfully treated basal cell carcinoma and squamous cell carcinoma of the skin or in situ cervical cancer. * Urinary tract infection (confirmed or suspected). * Other concomitant disorders considered by the investigator to affect the natural progression of the disease and significantly impact the treatment results. * Predictable unwillingness of the patient to adhere to the treatment regimen and/or cooperate with the investigator. * Participation of the patient in another clinical study within 3 months (6 months for biological medicinal products) prior to the inclusion visit or during this study.
Conditions Diabetes Mellitus, Diabetes Mellitus Typ...
Phase Not Applicable
Enrollment 220
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This observational study aims to understand why some adults with diabetes find it difficult to take their medicines as prescribed. Medication adherence is essential for controlling blood sugar levels and preventing complications, yet many patients face challenges that go beyond personal motivation. The study will examine multiple factors that may influence medication-taking behavior, including patients' understanding of their medicines, beliefs about treatment, family and social support, communication with healthcare providers, and practical issues such as medicine cost, availability, and distance to care. These factors will be analyzed using a structured behavioral framework to better understand how capability, opportunity, and motivation contribute to adherence. By identifying the most important barriers and supports across different levels, this research aims to provide evidence that can guide patient-centered care strategies and improve medication adherence in diabetes management.

Design

Study type: Observational Observational model: Case Only Time perspective: Cross Sectional

Interventions / Regimen

  • Other: Multilevel Ecological Determinants of Medication Adherence — Assessment of contextual and behavioral determinants associated with medication adherence among adults with diabetes receiving routine clinical care. Determinants include individual-level factors (medication literacy, beliefs about medicines), interpersonal factors (family involvement, social support), healthcare interaction factors (communication quality, regimen complexity), and structural/access-related factors (availability, affordability, distance). These exposures are measured through validated questionnaires and prescription review during a single outpatient encounter. No intervention is assigned as part of the study.

Primary Outcomes

  • Medication Adherence (Single assessment at enrollment (Day 1))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-12-15
Completion: 2026-08-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 220 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Malaya
Collaborators: Maharishi Markendeswar University (Deemed to be University)
Principal Investigators:
  • Rajat Rana, PhD (PRINCIPAL_INVESTIGATOR) - University of Malaya
Contact Information
Study Contact:
Rajat Rana, PhD
+91-9876543210
rajatrana91@gmail.com
Jyoti Jain, Pharm.D
+91-9876543210
jyotijj182@gmail.com
Kanika Dr
01731 304 100
rajat.rana@um.edu.my
MM Superspeciality Hospital, Maharishi Markandeshwar (Deemed to be University)
Interventions
  • Other: Multilevel Ecological Determinants of Medication Adherence — Assessment of contextual and behavioral determinants associated with medication adherence among adults with diabetes receiving routine clinical care. Determinants include individual-level factors (medication literacy, beliefs about medicines), interpersonal factors (family involvement, social support), healthcare interaction factors (communication quality, regimen complexity), and structural/access-related factors (availability, affordability, distance). These exposures are measured through validated questionnaires and prescription review during a single outpatient encounter. No intervention is assigned as part of the study.
Study Locations (1 sites)
MM Superspeciality Hospital, Maharishi Markandeshwar (Deemed to be University), Ambāla, Haryana India
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years or older * Diagnosed with at least one chronic disease (e.g., diabetes mellitus, hypertension, cardiovascular disease, chronic respiratory disease, chronic kidney disease) for a minimum duration of six months * Prescribed long-term medication therapy * Able to understand and respond to the study questionnaire * Willing to provide written informed consent Exclusion Criteria: * Patients with acute medical conditions requiring immediate care * Individuals with severe cognitive impairment or psychiatric illness that would preclude reliable participation * Patients who are terminally ill * Patients unwilling to participate or provide consent
Conditions Breast Cancer, Anthracycline Related Car...
Phase NA
Enrollment 30
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The main goal of this study is to test a virtual reality (VR) program, Survivors' Virtual Reality Survivorship Experience (SurviVRSE), designed to help Breast Cancer survivors (n=30) learn about heart health. The aims are to test the usability, feasibility, and acceptability o the intervention. Additionally, follow-up assessments will examine changes in women's cancer therapy related cardiac dysfunction knowledge and heart healthy behaviors (e.g., physical activity).

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Cardiovascular Health Education and Gaming through Virtual Reality — Prior to engaging the intervention, participants will complete a baseline survey. The virtual reality intervention will be delivered at one infusion treatment. Participants will complete all education modules and affiliated games. The education focuses on potentially cardiotoxic treatments (e.g., anthracyclines), ways to identify cancer treatment related cardiovascular dysfunction, and heart healthy behaviors that survivors can initiate during survivorship. Following the intervention participants will complete a survey similar to the baseline survey. One-month following the intervention participants will complete one final survey.

Primary Outcomes

  • CTRCD Knowledge (Baseline, within 2 days post-Intervention, and 4 weeks post-intervention)
  • Usability (Within 2 days post-Intervention)
  • Acceptability (Within 2 days post-Intervention)
  • User Satisfaction (Within 2 days post-Intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-20
Completion: 2027-09-28
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Virginia Commonwealth University
Principal Investigators:
  • Arnethea Sutton, Ph.D (PRINCIPAL_INVESTIGATOR) - Virginia Commonwealth University
Contact Information
Study Contact:
Arnethea Sutton, Ph.D
8048277363
careslab@vcu.edu
Victoria Williams
8048277363
williamsv4@vcu.edu
Victoria Williams
8048277363
williamsv4@vcu.edu
Adult Outpatient Pavilion
Interventions
  • Behavioral: Cardiovascular Health Education and Gaming through Virtual Reality — Prior to engaging the intervention, participants will complete a baseline survey. The virtual reality intervention will be delivered at one infusion treatment. Participants will complete all education modules and affiliated games. The education focuses on potentially cardiotoxic treatments (e.g., anthracyclines), ways to identify cancer treatment related cardiovascular dysfunction, and heart healthy behaviors that survivors can initiate during survivorship. Following the intervention participants will complete a survey similar to the baseline survey. One-month following the intervention participants will complete one final survey.
Study Locations (3 sites)
Adult Outpatient Pavilion, Richmond, Virginia 23220 United States
Cellular Immunotherapies and Transplant Department, Richmond, Virginia 23220 United States
VCU Health at Stony Point, Richmond, Virginia 23223 United States
Eligibility Criteria
Inclusion Criteria: * 18 years of age or older * Able to speak and read in English * Actively receiving Trastuzumab or an anthracycline-based treatment * Currently receiving immunotherapy. This includes pembrolizumab and atezolizumab. * Diagnosed with stages 0-III Breast Cancer Exclusion Criteria: \- History of prior Breast Cancer diagnosis (i.e., not their first breast cancer diagnosis)
Conditions Diabetes Type 2, Diabetes Type 1
Phase Not Applicable
Enrollment 150
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

People with diabetes are at increased risk of developing dementia, including Alzheimer's disease and vascular dementia. In addition, persons with diabetes have more pronounced age-related brain atrophy and cognitive difficulties compared to people without diabetes. The mechanisms behind the effects on the brain of diabetes are still unclear. New research suggests that the brains of some people with diabetes do not respond normally to insulin signals, a condition known as brain insulin resistance (BIR). To date, there have been no large clinical studies investigating BIR and its impact on brain health, but several smaller studies suggest that BIR may be a cause of cognitive decline and impaired brain health in people with diabetes. Another mechanism that may contribute to impaired brain health in people with diabetes is damage to the blood vessels in the brain. Damage to blood vessels is a well-known complication of diabetes, but how it affects the brain is not fully described. In this project, we will investigate the relationship between BIR and brain blood vessel dysfunction and its relationship to cognition and brain function. This is done by examining patients with type 1 diabetes (T1D), type 2 diabetes (T2D) and healthy controls. The participants will undergo MRI brain scans to assess the impact of BIR on the brain physiology and to evaluate brain blood vessel health. Participants will undergo comprehensive assessments of their cognitive abilities and thorough health examination.

Design

Study type: Observational Observational model: Case Control Time perspective: Cross Sectional

Primary Outcomes

  • Correlation between brain insulin response and cognitive measures (Baseline (only measured once))
  • Correlation between cerebrovascular reactivity and cognitive measures (Baseline (only measured once))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-01-01
Completion: 2032-01
Eligibility
Age: 50 Years and older
Sex: ALL
Volunteers: true
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Henrik Bo Wiberg Larsson
Collaborators: Steno Diabetes Center Copenhagen, University of Ulm
Principal Investigators:
  • Henrik BW Larsson, Professor (PRINCIPAL_INVESTIGATOR) - Rigshospitalet, Denmark
  • Jørgen Rungby, Professor (PRINCIPAL_INVESTIGATOR) - Steno Diabetes Center Copenhagen
  • Flemming Pociot, Professor (PRINCIPAL_INVESTIGATOR) - Steno Diabetes Center Copenhagen
Contact Information
Study Contact:
Henrik BW Larsson, Professor
+45 24824294
henrik.bo.wiberg.larsson@regionh.dk
Interventions
N/A
Study Locations (3 sites)
Rigshospitalet, Glostrup Municipality, 2600 Denmark
Steno Diabetes Center Copenhagen, Herlev, 2730 Denmark
University of Ulm, Ulm, 89081 Germany
Eligibility Criteria
Inclusion Criteria (all): * age 50-80 years Inclusion Criteria (diabetes only): * Diagnosis of either type 1 diabetes or type 2 diabetes * Diabetes duration of ≥10 years for individuals with type 1 diabetes and ≥5 years for individuals with type 2 diabetes Exclusion Criteria: * HbA1c \>100 mmol/mol * Other type of diabetes * Weight \>140 Kg * Treatment with drugs that cannot be paused for 12 hours * Diagnosis of dementia * Active and recent (1year) malignant disease * History of major stroke * Major depression and/or treatment with antipsychotics * History of traumatic brain injury * Other medical condition or disorder (e.g., epilepsy, recent concussion) that in the opinion of the investigator precludes compliance with the protocol, evaluation of the results or represent an unacceptable risk for the participant's safety. * Inability to perform neuropsychological tests (e.g., severe vision and hearing impairment that cannot be improved with aids such as glasses and hearing aids, or language barrier.) * Severe claustrophobia * Foreign bodies of metal in the body which prohibits brain MRI scans (e.g. pacemaker or screws/plates from surgery in the head or neck region) * Participants who do not wish to be informed about accidental findings by MRI * eGFR measurement \<45 within 3 months of study visit
Conditions Cardiovascular Disease (CVD), Heart Fail...
Phase Not Applicable
Enrollment 5000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will collect physiologic data in patients with cardiovascular conditions and observe the natural history of those conditions for research purposes.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Longitudinal Assessment of Clinical Status (Baseline through each 90-day cycle)
  • Longitudinal Assessment of Clinical Status (Baseline through each 90-day cycle)
  • Longitudinal Assessment of Clinical Status (Baseline through each 90-day cycle)
  • Longitudinal Assessment of Clinical Status (Baseline through each 90-day cycle)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-10-30
Completion: 2030-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 5000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Prolaio
Contact Information
Study Contact:
Study Team OCORO Study
1-855-869-9054
OCOROstudy@prolaio.com
Interventions
N/A
Study Locations (1 sites)
Prolaio, Chicago, Illinois 60606 United States
Eligibility Criteria
Inclusion Criteria: * 18 years of age and older * Ability to understand study assessments and give informed consent to data collection * Ability to comply with the study protocol * Ability to understand and respond to instructions in English * Has diagnosis of qualifying Cardiovascular Disease(s), including but not limited to: HF, AS, HCM, HTN, DCM, etc. Additional CVD may be included at discretion of the investigators. * Resides in the United States Exclusion Criteria: * Allergy to adhesive used in biosensor patch * Life-threatening disease process outside of area under study, such as actively treated cancer or being actively considered for organ pre-transplant (such as hepatic failure; end-stage renal disease). * Severe CVD defined by hospital admission for cardiac diagnosis within 30 days of enrollment or documentation of NYHA functional class IV * \-- For participants who do not qualify due to this exclusion, and have not been hospitalized within 30 days of enrollment, they may reapply to enroll in the study * Self-reported weight of 400 pounds or greater
Conditions Breast Cancer, Chemotherapy-induced Peri...
Phase NA
Enrollment 384
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

As a core component of comprehensive breast cancer treatment, chemotherapy frequently induces chemotherapy-induced peripheral neuropathy (CIPN), particularly with taxane-based agents. The incidence of CIPN reaches 68.1% within the first month of chemotherapy, and over 30% of patients experience persistent symptoms for more than 6 months. The resulting sensorimotor dysfunction significantly impairs patients' quality of life, necessitates dose reduction or treatment discontinuation, and ultimately affects survival outcomes. Currently, no prophylactic pharmacological or non-pharmacological interventions have received Grade I recommendations in domestic or international guidelines and expert consensuses. The compression therapy demonstrated definite preventive value in the POLAR trial. Its low cost and high tolerability confer substantial clinical applicability, earning it a Grade III recommendation in ESMO guidelines. Meanwhile, single-arm trials of acupuncture have reported a 51.2% symptom relief rate and a trend toward reduced high-grade CIPN. As non-pharmacological interventions, acupuncture and compression therapy hold complementary potential in preventing taxane-induced CIPN: compression therapy locally blocks drug exposure, while acupuncture systemically regulates neural function.However, three core challenges persist in the current research field: insufficient evidence quality for single-intervention strategies, lack of systematic evaluation of combined interventions, and the absence of risk-stratified prevention models. To address these gaps, this study aims to conduct a prospective randomized controlled trial to concurrently evaluate the preventive efficacy of compression therapy, acupuncture, and their combination for taxane-induced CIPN. The goal is to provide high-level evidence-based medicine to support the development of individualized prevention strategies.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Other: Compression — Two layers of latex gloves are worn on both hands, and Class II compression stockings are worn on both feet. The devices are donned 30 minutes before chemotherapy initiation and removed 30 minutes after chemotherapy completion.
  • Other: Acupuncture — Acupuncture is administered consecutively for 3-5 days starting from Day 1 post each chemotherapy cycle, with electrical stimulation applied for 20-30 minutes per session. The selected acupoints included: PC6, LI4, SI3, ST36, SP6, LR3, SP4, EX-LE10.
  • Other: Sham acupuncture — A shallow needling at non-acupoint sites (sham acupuncture) is adopted. The stimulation locations are non-acupoint areas 1-2 cun away from the standard acupoint positions. For the sham acupuncture group, needles are inserted superficially to a depth of 2-3 mm without manipulation, with the endpoint of no deqi sensation. Operational elements including needle type, patient posture, disinfection method, needle insertion technique, needle retention time, and needle withdrawal technique are identical between the sham acupuncture group and the active acupuncture group.
  • Other: Compression combined with acupuncture — Two layers of latex gloves are worn on both hands, and Class II compression stockings are worn on both feet. The devices are donned 30 minutes before chemotherapy initiation and removed 30 minutes after chemotherapy completion. Acupuncture is administered consecutively for 3-5 days starting from Day 1 post each chemotherapy cycle, with electrical stimulation applied for 20-30 minutes per session. The selected acupoints included: PC6, LI4, SI3, ST36, SP6, LR3, SP4, EX-LE10.

Primary Outcomes

  • Incidence of grade ≥2 CIPN at 12 weeks after the initiation of chemotherapy (12 weeks after the initiation of chemotherapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-01
Completion: 2028-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 384 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Information
Study Contact:
Jieqiong Liu
86-13922272706
liujieqiong01@163.com
Jieqiong Liu
086-13922272706
liujieqiong01@163.com
Breast Tumor Center, Sun Yat-sen Memorial Hospital
Interventions
  • Other: Compression — Two layers of latex gloves are worn on both hands, and Class II compression stockings are worn on both feet. The devices are donned 30 minutes before chemotherapy initiation and removed 30 minutes after chemotherapy completion.
  • Other: Acupuncture — Acupuncture is administered consecutively for 3-5 days starting from Day 1 post each chemotherapy cycle, with electrical stimulation applied for 20-30 minutes per session. The selected acupoints included: PC6, LI4, SI3, ST36, SP6, LR3, SP4, EX-LE10.
  • Other: Sham acupuncture — A shallow needling at non-acupoint sites (sham acupuncture) is adopted. The stimulation locations are non-acupoint areas 1-2 cun away from the standard acupoint positions. For the sham acupuncture group, needles are inserted superficially to a depth of 2-3 mm without manipulation, with the endpoint of no deqi sensation. Operational elements including needle type, patient posture, disinfection method, needle insertion technique, needle retention time, and needle withdrawal technique are identical between the sham acupuncture group and the active acupuncture group.
  • Other: Compression combined with acupuncture — Two layers of latex gloves are worn on both hands, and Class II compression stockings are worn on both feet. The devices are donned 30 minutes before chemotherapy initiation and removed 30 minutes after chemotherapy completion. Acupuncture is administered consecutively for 3-5 days starting from Day 1 post each chemotherapy cycle, with electrical stimulation applied for 20-30 minutes per session. The selected acupoints included: PC6, LI4, SI3, ST36, SP6, LR3, SP4, EX-LE10.
Study Locations (1 sites)
Breast Tumor Center, Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong 510000 China
Eligibility Criteria
Inclusion Criteria: 1. Age 18-70 years old and have signed an informed consent form; 2. Patients with histologically confirmed non-recurrent early or intermediate-stage breast cancer; 3. Patients scheduled to receive cyclical adjuvant or neoadjuvant chemotherapy based on taxane drugs (4-cycle or single-cycle regimen); 4. No prior exposure to breast cancer-related chemotherapy, immunotherapy, or endocrine therapy; 5. Cardiac echocardiography showing cardiac ejection fraction within normal range; 6. Eastern Cooperative Oncology Group (ECOG) physical status ≤1; 7. No psychiatric or cognitive impairments, capable of understanding and completing assessment scales; 8. No CIPN at baseline (NCI-CTCAE 5.0 and TNSc grading ≤0); 9. Good organ function meeting the following criteria: Hb ≥90g/L, WBC ≥3.5×10⁹/L, platelets ≥100×10⁹/L, neutrophils ≥1.5×10⁹/L, AST ≤3× upper limit of normal, ALT ≤3× upper limit of normal, bilirubin ≤1.5× upper limit of normal, serum creatinine ≤1.5× upper limit of normal; 10. Fertile women must agree to use effective contraception for 7 days before first dosing through 24 weeks post-treatment. Fertile women must have a negative serum pregnancy test within 7 days before first dosing. Exclusion Criteria: 1. Patients with active infections, skin lesions on hands/feet, or contraindications to chemotherapy, acupuncture, or compression therapy; 2. Patients with prior exposure to neurotoxic agents (e.g., taxanes, oxaliplatin, platinum-based drugs, vincristine) or platinum-containing chemotherapy regimens; 3. Patients who received acupuncture for other conditions within the past month; 4. Patients with conditions predisposing to peripheral neuropathy symptoms (e.g., alcoholism, uremia, diabetes, autoimmune disorders, rheumatoid arthritis, cervical spondylosis, severe mental illness, severe trauma); 5. Patients with Raynaud's syndrome, cold intolerance, peripheral arterial ischemia, or hand-foot syndrome; 6. Patients receiving medications that may mask CIPN symptoms (e.g., SSNRI, SSRI, tricyclic antidepressants, B-complex vitamins); 7. Patients with lymphedema in acupuncture stimulation areas; 8. Patients with phobia of electroacupuncture or stainless steel needle allergy; 9. Patients with severe non-malignant conditions that may compromise treatment adherence or pose risks; 10. Patients undergoing concurrent anti-tumor therapy or clinical trials; 11. Patients with dementia, cognitive impairment, or psychiatric conditions affecting informed consent comprehension; 12. Patients with known allergy history or contraindications to trial procedures; 13. Patients with uncontrolled cardiac symptoms or conditions, including: (1) NYHA class 2 or higher heart failure; (2) unstable angina; (3) myocardial infarction within the past year; (4) clinically significant supraventricular or ventricular arrhythmias requiring treatment; 14. Cardiac pacemaker implantation; 15. Known hereditary or acquired bleeding/thrombosis predispositions (e.g., hemophilia, coagulation disorders, thrombocytopenia, hypersplenism, etc.).
Conditions Major Depressive Disorder (MDD)
Phase NA
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Major depressive disorder (MDD) is one of the most common psychiatric conditions and often remains difficult to treat effectively. Many patients continue to experience residual symptoms or relapse even after receiving established forms of psychotherapy. This study tests whether targeting specific psychological mechanisms can improve outcomes for people with depression. We compare two novel group therapies: (1) Expectation-Focused Psychotherapeutic Intervention (EFPI), which aims to modify rigid, negative expectations that maintain depressive symptoms, and (2) Reward Enhancement and Activation Therapy (REACT), which focuses on increasing sensitivity to positive experiences and strengthening reward-related learning. Both are delivered in a group format to foster peer support and shared learning. A total of 150 adults with a current MDD diagnosis will be randomly assigned to EFPI, REACT, or a waiting-list control. Participants in the intervention groups receive 10 group sessions over five weeks. Waiting-list participants complete baseline and 3-month follow-up assessments before being offered standard treatment options. Clinical outcomes are assessed at baseline, immediately after treatment, and at 3- and 6-month follow-ups (for the intervention groups). Primary outcomes are reductions in depressive symptoms measured by clinician ratings and self-report questionnaires. Secondary outcomes include changes in expectation processes and reward sensitivity. In addition, functional MRI (fMRI) tasks examine brain mechanisms related to expectation updating and reward processing pre- and post-intervention, to help identify neural changes that may underlie symptom improvement. By directly addressing dysfunctional expectations and reduced reward sensitivity, this study seeks to provide evidence for more targeted psychotherapeutic approaches. If successful, the results may support more personalized treatments and better long-term outcomes in MDD.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Expectation-Focused Psychotherapeutic Intervention — EFPI is a manualized group psychotherapy for major depressive disorder that directly targets maladaptive expectations. The treatment integrates psychoeducation, cognitive restructuring, and behavioral experiments to modify negative expectancies and reduce cognitive immunization, thereby enhancing adaptive expectation updating. Delivery: Group format (5-10 participants), 10 sessions (twice weekly for 5 weeks).
  • Behavioral: Reward Enhancement and Activation Therapy — REACT is a manualized group psychotherapy for major depressive disorder that focuses on enhancing reward sensitivity and motivation. The intervention combines attentional retraining, savoring techniques, and reinforcement-based strategies to increase engagement with rewarding stimuli and experiences. Delivery: Group format (5-10 participants), 10 sessions (twice weekly for 5 weeks).

Primary Outcomes

  • Change in Depressive Symptoms (Beck Depression Inventory-II) (Baseline, post-treatment (5 weeks), 3-month and 6-month follow-ups)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-13
Completion: 2028-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Philipps University Marburg
Collaborators: German Research Foundation
Principal Investigators:
  • Winfried Rief, Prof. Dr. (PRINCIPAL_INVESTIGATOR) - Philipps University Marburg
Contact Information
Study Contact:
Masia Fernanda Hoffmann, M.Sc.
+4917656538480
fernanda.hoffmann@uni-marburg.de
Winfried Rief, Prof. Dr.
+49 6421 282 3657
rief@staff.uni-marburg.de
Masia Fernanda Hoffmann, M.Sc.
+4917656538480
fernanda.hoffmann@uni-marburg.de
Philipps-University Marburg
Interventions
  • Behavioral: Expectation-Focused Psychotherapeutic Intervention — EFPI is a manualized group psychotherapy for major depressive disorder that directly targets maladaptive expectations. The treatment integrates psychoeducation, cognitive restructuring, and behavioral experiments to modify negative expectancies and reduce cognitive immunization, thereby enhancing adaptive expectation updating. Delivery: Group format (5-10 participants), 10 sessions (twice weekly for 5 weeks).
  • Behavioral: Reward Enhancement and Activation Therapy — REACT is a manualized group psychotherapy for major depressive disorder that focuses on enhancing reward sensitivity and motivation. The intervention combines attentional retraining, savoring techniques, and reinforcement-based strategies to increase engagement with rewarding stimuli and experiences. Delivery: Group format (5-10 participants), 10 sessions (twice weekly for 5 weeks).
Study Locations (1 sites)
Philipps-University Marburg, Marburg, Hesse 35032 Germany
Eligibility Criteria
Inclusion Criteria: * Age: 18-80 years * Current diagnosis of major depressive disorder (MDD) according to DSM-5, confirmed by structured clinical interview (e.g., DIPS) * Hamilton Depression Rating Scale (HAMD-21) score ≥ 9 * Ability to attend group therapy sessions (2×/week for 5 weeks) * Ability to undergo MRI scanning (for participants in the fMRI component) Written informed consent Exclusion Criteria: * Current or lifetime diagnosis of bipolar disorder, psychotic disorder, or primary substance use disorder * High acute suicide risk requiring immediate intervention * Severe neurological disorder, brain injury, or contraindications for MRI (e.g., metal implants, claustrophobia) * Ongoing psychotherapy or initiation of a new antidepressant medication within the past 4 weeks * Insufficient German language proficiency to participate in therapy and complete study assessments * Cognitive impairment or other conditions interfering with informed consent or study participation
Conditions Locally Advanced or Metastatic Breast Ca...
Phase PHASE3
Enrollment 912
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The study is being conducted to evaluate the efficacy and safety of HRS-8080 combined with dalpiciclib versus fulvestrant combined with dalpiciclib in patients with locally advanced/metastatic breast cancer who had developed drug resistance to prior adjuvant endocrine therapy.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: HRS-8080 Tablet ; Dalpiciclib Isethionate — * HRS-8080 Tablet * Dalpiciclib Isethionate
  • Drug: Fulvestrant injection ;Dalpiciclib Isethionate — * Fulvestrant injection * Dalpiciclib Isethionate

Primary Outcomes

  • Investigator assessed Progression free survival (PFS) (Up to 5 years.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-05-05
Completion: 2031-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 912 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shandong Suncadia Medicine Co., Ltd.
Contact Information
Study Contact:
Zhan Zhang
+86 17721286165
Zhan.zhang@hengrui.com
Zefei Jiang
Chinese PLA General Hospital Fifth Medical Center
Interventions
  • Drug: HRS-8080 Tablet ; Dalpiciclib Isethionate — * HRS-8080 Tablet * Dalpiciclib Isethionate
  • Drug: Fulvestrant injection ;Dalpiciclib Isethionate — * Fulvestrant injection * Dalpiciclib Isethionate
Study Locations (1 sites)
Chinese PLA General Hospital Fifth Medical Center, Beijing, Beijing Municipality 100000 China
Eligibility Criteria
Inclusion Criteria: 1. Women aged 18 - 75 years old; 2. Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 to 1; 3. Patients with histologically confirmed locally advanced or metastatic breast cancer; 4. Patients with prior adjuvant endocrine resistance following curative-intent surgery; 5. Menstrual status: postmenopausal, perimenopausal, or premenopausal; 6. Presence of evaluable lesions; 7. Organ function must meet required criteria. Exclusion Criteria: 1. Patients with rapidly progressing disease, as judged by the investigator to be unsuitable for endocrine therapy; 2. Patients who have previously received fulvestrant or other novel SERMs (excluding tamoxifen and toremifene); 3. Patients with uncontrolled brain metastases, carcinomatous meningitis, or spinal cord compression; 4. Patients with a history of clinically significant cardiovascular disease; 5. Participants who have not recovered from adverse effects caused by prior therapies; 6. Participants with a history of another malignancy within the past 5 years or currently having another malignancy; 7. Known hypersensitivity to HRS-8080, fulvestrant, dalpiciclib, or any of their components, etc.